Symptomatic Neurogenic Orthostatic Hypotension
7 clinical trials · Condition
◉ Watch Symptomatic Neurogenic Orthostatic Hypotension
| Record | Firm | Date |
|---|---|---|
| Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (NCT04095793) | Theravance Biopharma | 2019-09-19 |
| Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (NCT03829657) | Theravance Biopharma | 2019-02-22 |
| Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (NCT03750552) | Theravance Biopharma | 2019-01-24 |
| Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension (NCT02586623) | H. Lundbeck A/S | 2016-02-11 |
| A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy (NCT01927055) | Chelsea Therapeutics | 2013-11-01 |
| Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa (NCT01149629) | Chelsea Therapeutics | 2010-07-01 |
Track Symptomatic Neurogenic Orthostatic Hypotension automatically
Every clearance here is in the API, with alerts when new ones post.